Table 3 Average number of months and percent of time spent on buprenorphine above and below retention thresholds based on retention definitions each opioid use disorder treatment stage restricted to 4 years after initiating buprenorphine treatment among patients with HIV and opioid use disorder by retention definition in the Johns Hopkins HIV Clinical Cohort, 2013–2020
Retention definition | On Buprenorphine below retention threshold | On buprenorphine at/above retention threshold | ||
|---|---|---|---|---|
| Â | Months | Percent | Months | Percent |
1. ≥ 180 days of treatment without > 7-day gap | 7.5 (6.1, 8.9) | 16 (13, 19) | 6.5 (4.6, 8.5) | 13 (10, 18) |
2. ≥ 180 days of treatment without > 30-day gap | 6.8 (5.6, 8.2) | 14 (12, 17) | 7.3 (5.3, 9.4) | 15 (11, 20) |
3. ≥ 90 days of treatment without > 7-day gap | 5.3 (4.1, 6.6) | 11 (9, 14) | 8.4 (6.2, 10.7) | 18 (13, 22) |
4. ≥ 90 days of treatment without > 30-day gap | 4.4 (3.5, 5.4) | 9 (7, 11) | 9.6 (7.4, 11.8) | 20 (15, 25) |